Most Active Biotech Investors in South San Francisco 2026

15 firms writing Biotech checks in South San Francisco, led by AME Cloud Ventures, Breakout Ventures.

Biotech in South San Francisco accounts for 15 tracked companies with verified cap-table data, 15 of which disclose round sizes totalling $3.4B. The median disclosed raise is $200M, and the largest is ORIC Pharmaceuticals at $900M, ahead of Alumis ($529M) and Terremoto Biosciences ($250M).

The names that recur most often on these biotech cap tables are Alexandria Venture Investments (5 companies), Eli Lilly and Company (4 companies), Janus Henderson Investors (3 companies), EcoR1 Capital (2 companies), Foresite Capital (2 companies), venBio Partners (2 companies). By latest disclosed round, the market skews Series B (5), Series A (4), Series D (3), IPO (1).

Best funded Biotech in South San Francisco companies

  1. ORIC Pharmaceuticals — $900M (latest: IPO)
  2. Alumis — $529M (latest: Series C)
  3. Terremoto Biosciences — $250M (latest: Series B)
  4. Lycia Therapeutics — $232M (latest: Series D)
  5. SonoThera — $215M (latest: Series B)
  6. Neuron23 — $214M (latest: Series D)
  7. Attralus — $201M (latest: Series B)
  8. Tenvie Therapeutics — $200M (latest: Series A)
  9. TRex Bio — $193M (latest: Series B)
  10. Trace Neuroscience — $101M (latest: Series A)
  11. Star Therapeutics — $100M (latest: Series D)
  12. Addition Therapeutics — $100M
  13. IgGenix — $65M (latest: Series B)
  14. Dualitas Therapeutics — $65M (latest: Series A)
  15. Calithera Biosciences — $40M (latest: Series A)

Sector × city funding reports (20)

All research · Investor directory · Company funding database · Fundraising library